Results 61 to 70 of about 743 (109)

Intravenous Brivaracetam in the treatment of status epilepticus: a systematic review

, 2019
BACKGROUND: Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A ligand with high brain permeability and rapid onset of action. These properties make brivaracetam potentially an ideal compound in the emergency setting.
Nardone, Raffaele, Trinka, Eugen, Nardone R., Lattanzi S., Brigo F., Brigo, Francesco, Lattanzi, Simona, Trinka E.   +7 more
core   +1 more source

Outcome Analysis in Epilepsy Patients Undergoing Switchover from Levetiracetam to Brivaracetam

Archives of Medicine and Health Sciences
Background and Aim: Epilepsy is a chronic noncommunicable disorder causing repeated seizures, which are characterized by abnormal electrical discharges in the brain.
Agna Maria Rejy, Ananya S Prasad, Anju Susan Babu, Abijith P Biju, R. Lakshmi, P. A. Daisy, A. V. Sreeram Prasad   +6 more
doaj   +1 more source

Real‐world use of Cenobamate in pediatric drug‐resistant epilepsy: A European multicenter retrospective study

Epilepsia Open, Volume 11, Issue 5, Page 1863-1870, October 2026.
Abstract Pediatric drug‐resistant epilepsy (DRE) remains a significant clinical challenge, with few effective pharmacological options. This European multicenter retrospective study assessed the real‐world efficacy, tolerability, and retention of off‐label cenobamate (CNB) in 108 children and adolescents with DRE (median age: 13.83 years, range 3.9–19.8)
Konstantin L. Makridis, Thomas Bast, Stéphane Auvin, Pavel Krsek, Matyas Ebel, Eva Breuer, Mira Beckhaus, Matúš Bašovský, Pavlína Danhofer, Ondřej Horák, Alessandro Orsini, Gonzalo Alonso Ramos Rivera, Hana Medřická, Steffen Syrbe, Angela M. Kaindl   +14 more
wiley   +1 more source

A review of the pharmacology and clinical efficacy of brivaracetam

, 2018
Pavel Klein,1 Anyzeila Diaz,2 Teresa Gasalla,3 John Whitesides4 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; 2Neurology Patient Value Unit, UCB Pharma, Smyrna, GA, USA; 3Neurology Patient Value Unit, UCB Pharma, Monheim am Rhein, Germany ...
Diaz A, Klein P, Whitesides J, Gasalla T
core  

First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

BMJ Open, 2019
Objectives Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting.Design Retrospective ...
Katja Menzler, Peter Michael Mross, Felix Rosenow, Susanne Schubert-Bast, Laurent Maximilian Willems, Felix Zahnert, Ilka Immisch, Sven Fuest, Felix von Podewils, Rhina Kunz, Martin Hirsch, Tamara Mueller, Justus Marquetand, Yaroslav Winter, Lisa Langenbruch, Michal Cicanic, Stefan Beyenburg, Adam Strzelczyk, Susanne Knake   +18 more
doaj   +1 more source

Bridging computational and clinical strategies for presurgical identification of epileptogenic networks

Epilepsia Open, Volume 11, Issue 5, Page 1525-1540, October 2026.
Abstract Objective About one third of epilepsy patients are drug‐resistant. Resective epilepsy surgery remains a key treatment option but depends critically on accurate identification of the seizure onset zone (SOZ), which is still guided mainly by subjective visual inspection of electrophysiological signals.
Tena Dubcek, Debora Ledergerber, Kristina Koenig, Adham Elshahabi, Rafael Polania, Lukas Imbach   +5 more
wiley   +1 more source

Fotocatálise assimétrica aplicada à síntese formal do medicamento brivaracetam

, 2023
Seminário de Iniciação CientíficaNeste trabalho, apresentamos a síntese formal do fármaco antiepiléptico Brivaracetam. Trata-se de um fármaco quiral, que é comercializado na forma de apenas um esteroisômero.
Flores, Lara Flores
core  

Brivaracetam‐associated manic episode in a patient with bipolar disorder: A case report

PCN Reports
Background Levetiracetam and brivaracetam (BRV) are antiseizure medications that exert effects by binding to synaptic vesicle protein 2A (SV2A). BRV exhibits higher affinity and selectivity for SV2A and is generally considered to have a favorable ...
Mihoko Kawai, Jun Miyata, Kousuke Kanemoto   +2 more
doaj   +1 more source

Impact of Third-Generation Antiseizure Medications on People with Epilepsy in a Low-Income Population: The Brivaracetam Experience in a Real-World Study

Drugs - Real World Outcomes
Background Third-generation antiseizure medications, such as brivaracetam, are recognized for their superior safety, tolerability, and pharmacokinetic profiles.
Camilo Espinosa-Jovel, Natalia Valencia, Lisa Gaitán, Sandra Riveros   +3 more
doaj   +1 more source

Comparative analysis of brivaracetam and levetiracetam in epilepsy treatment

Tungs’ Medical Journal
Epilepsy affects millions of people worldwide, necessitating effective and safe treatment options. Brivaracetam (BRV) and levetiracetam (LEV) are antiepileptic drugs that target the synaptic vesicle protein 2A (SV2A).
Ming-Yuan Hsu, Shu-Wei Hu, Hueng-Chuen Fan   +2 more
doaj   +1 more source